Search
Filter Results
Displaying 271–280 of 723 for “Visions 2020”
-
Jun 1, 2017
Valproic Acid's Effect Too Small in One-Year Clinical Trial
While a therapy for adRP will not emerge from the clinical trial, study investigators advanced development of a new outcome measure known as EZ Area to quickly and accurately evaluate potential therapies for RP in human studies.
-
Aug 18, 2016
Optogenetic Therapy Takes First Step Forward in Clinical Trial
RetroSense’s optogenetic therapy is designed to restore vision to people who are completely blind from retinal degenerative diseases such as retinitis pigmentosa by bestowing light sensitivity to retinal ganglion cells, which survive after photoreceptors, the cells that make vision possible, are lost.
-
Apr 14, 2015
Need-to-Know Information about Clinical Trials
A primer on what you can expect from clinical trials.
-
Oct 10, 2014
Genetics 101: How Some Retinal Diseases are Inherited
To understand heredity, you have to know a little about genetics. Below is a review of the three major genetic-disease inheritance patterns.
-
Nov 6, 2012
Thanks to recent advances in stem cell research, we are getting closer to replacing cells in the retina lost to diseases such as retinitis pigmentosa and age-related macular degeneration.
-
May 3, 2012
The FDA's Indispensible Role (a guest blog from Dr. Patricia Zilliox)
While it may not seem obvious, the FDA ultimately drives everything — the researchers and the money. That’s because without FDA approval, you have no treatment, even if you have great research and adequate funding.
-
Mar 21, 2012
The Importance of Stem Cells (a guest post from Dr. David Gamm)
Dr. David Gamm on the potential of stem cell research to benefit patients with retinal degenerations.
-
Jan 26, 2011
The study is designed to evaluate the pharmacodynamics, safety and tolerability of emixustat in subjects with macular atrophy secondary to Stargardt disease.
-
May 17, 2022
AGTC’s XLRP Gene Therapy Performs Well in Extension of Phase 2 Clinical Trial
The three-month results support the planned launch of the company’s Phase 2/3 Vista trial
-
Oct 25, 2021
FDA Approves Genentech’s Susvimo for Treating Wet AMD
The approach significantly reduces the need for regular ocular injections.